CSTL News

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

Merlin CP-GEP Becomes the First and Only Gene Expression Profile (GEP) Test Recommended by NCCN® Cutaneous Melanoma Guidelines to Assess Metastatic Risk

Orion Nuclear Energy Corporation and Constellis Announce Strategic Collaboration to Advance Security Standards for Nuclear and Critical Infrastructure

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma